drugset / Trial / NCT05553717

Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy

NCT05553717

Unknown 66 enrolled Tanta University
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to investigate the possible efficacy of Carvedilol as gastroprotective agent against aspirin-induced upper gastro-intestinal complications in patients with ischemic heart disease (IHD).

Timeline

Start
2022-10
Primary completion
2023-10
Completion
2023-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carvedilol Other / unclassified 12.5 mg